Zevra Therapeutics Stock Earnings Reports

Key points for investors: Zevra reported strong Q1 2026 commercial and financial performance driven by MIPLYFFA (Arimoclomol) for Niemann-Pick disease type C (NPC). Total net revenue was $36.2 million, a 78% increase vs. Q1 2025, comprised primarily of $24.6M U.S. MIPLYFFA sales and $10.2M in net reimbursements from the global Expanded Access Program (EAP). Since launch through March 31, Zevra received 170 prescription enrollment forms for MIPLYFFA (9 in Q1) and reports roughly a 50/50 adult–pediatric mix; management estimates U.S. diagnosed NPC patients at ~300–350 and total prevalence ~900. The company has 122 patients enrolled in the global EAP and has an MAA under EMA review (responses to the 120-day questions submitted). MIPLYFFA was added to updated NPC clinical practice guidelines, strengthening clinical positioning and reinforcing combination therapy with miglustat. Commercial execution highlights include an AI-driven patient identification model, genetic-testing collaborations, an Expert Connect program for HCP education, and payer coverage of ~69% of lives with continued use of medical-exception pathways. Late-stage pipeline: the DiSCOVER Phase III trial of Celiprolol for Vascular Ehlers-Danlos Syndrome (vEDS) has enrolled 62 patients (10 in Q1); the study is event-driven and has had 2 of the 28 events required for interim analysis. Corporate/financial moves: Zevra sold noncore SDX assets to Commave for $50M (net proceeds largely received), recorded a ~$43.3M one-time gain, paid off debt early (now debt-free), and reported cash, cash equivalents and investments of $236.8M. GAAP net income was $37.9M ($0.62 basic, $0.60 diluted) driven by one-time items; adjusted for one-offs, quarterly net income would be ~$11.5M ($0.18 diluted). Operating expenses rose modestly (R&D $4.4M; SG&A $20.8M). Key near-term catalysts: continued MIPLYFFA launch execution and diagnostics expansion, EMA review outcome, additional enrollment/events in the Celiprolol Phase III trial and a planned follow-up FDA meeting in H2 2026 to discuss acceleration pathways for Celiprolol.